Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

López-Alvarenga, Juan Carlos; Orr, William C.; Vargas-Romero, J.A.; Troche, José María Remes; Morales-Arámbula, M.; Soto-Pérez, Julio César; Mateos-Pérez, G.; Sobrino-Cossío, Sergio; Teramoto-Matsubara, Óscar; López‐Colombo, Aurelio; Orozco-Gamiz, Antonio; Sáez-Ríos, A.; Arellano-Plancarte, Araceli; Chiu-Ugalde, Jazmin; Tholen, Anne; Horbach, Silke; Lundberg, Lena; Fass, Ronnie

doi:10.5056/jnm.2014.20.1.64

Cited by 9 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerning studies conducted with ReQuest in Mexico, this tool has been used to measure symptoms intensity before and following dosing of pantoprazole magnesium; however, its diagnostic efficacy is unknown. 19 Interestingly, our study compared to other studies explored the diagnostics usefulness of GerdQ considering the different phenotypes of GERD and establishing thus, that most of the patients with erosive GERD and NERD with abnormal pHMetry had scores ＞ 8, meanwhile most of the patients with functional heartburn and hypersensitive esophagus had scores ＜ 8. That means there seems to be a relation indicating that the high score and higher likelihood of a more aggressive disease; meanwhile on the other hand patients with lower scores but with recurrent symptoms might belong to the spectrum of functional patients with GERD.…”

Section: Discussionmentioning

confidence: 71%

Validation and Diagnostic Usefulness of Gastroesophageal Reflux Disease Questionnaire in a Primary Care Level in Mexico

Zavala-Gonzáles¹,

Azamar-Jácome²,

Meixueiro-Daza³

et al. 2014

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/Aims Different non-invasive diagnostics strategies have been used to assess patients with gastroesophageal reflux. Gastroesophageal reflux disease (GERD) questionnaire (GerdQ) is a 6-item, easy to use questionnaire that was developed primarily as a diagnostic tool for GERD in primary care. Our aim was to validate and assess diagnostic utility of GerdQ questionnaire in Mexican patients in the primary care setting. Methods The study was performed in 3 phases: (1) a questionnaire translation and comprehension study (n = 20), (2) are a reproducibility and validation study (50 patients and 50 controls) and (3) a study to assess the clinical utility in 252 subjects with GERD symptoms. Diagnostic accuracy was calculated using endoscopy and/or pH-metry as the gold standard. Results Internal consistency measured by the Cronbach’s α coefficient was 0.81 for patients and 0.90 for healthy controls, with a mixed coefficient of 0.93. Reproducibility for GerdQ was very good and its discriminating validity was 88%. Most of the patients with erosive reflux and non-erosive reflux with abnormal pH-metry had scores > 8, meanwhile most of the patients with functional heartburn and hypersensitive esophagus had < 8. Sensitivity, specificity and positive predictive value of GerdQ com -pared to the gold standard were 72%, 72% and 87%, respectively. Conclusions In Mexico, the GerdQ questionnaire Spanish validated version is useful for GERD diagnosis in the primary care setting.

show abstract

Section: Discussionmentioning

confidence: 71%

Validation and Diagnostic Usefulness of Gastroesophageal Reflux Disease Questionnaire in a Primary Care Level in Mexico

Zavala-Gonzáles¹,

Azamar-Jácome²,

Meixueiro-Daza³

et al. 2014

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…This questionnaire was tried out in Germany, France, Spain, the United Kingdom, and the United States [30,31], and has been translated into different languages to be applied in various locations including Mexico [32,33]. In addition to this questionnaire, participants also filled out a questionnaire of socio-demographic characteristics.…”

Section: Methodsmentioning

confidence: 99%

“…Severity of GERD symptoms was assessed by the ReQuest in Practice questionnaire consisting of six dimensions (general well-being, acidity complaints, lower abdominal complaints, upper abdominal complaints, nausea, and sleep disturbances) using a visual analog scale of 10 cms, referring to the severity of these symptoms in the last 24 hours. This questionnaire was tried out in Germany, France, Spain, the United Kingdom, and the United States [ 30 , 31 ], and has been translated into different languages to be applied in various locations including Mexico [ 32 , 33 ]. In addition to this questionnaire, participants also filled out a questionnaire of socio-demographic characteristics.…”

Section: Methodsmentioning

confidence: 99%

Heritability and genetic correlation between GERD symptoms severity, metabolic syndrome, and inflammation markers in families living in Mexico City

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to estimate the heritability (h2) and genetic correlation (ρG) between GERD symptoms severity, metabolic syndrome components, and inflammation markers in Mexican families.MethodsCross-sectional study which included 32 extended families resident in Mexico City. GERD symptoms severity was assessed by the ReQuest in Practice questionnaire. Heritability and genetic correlation were determined using the Sequential Oligogenic Linkage Analysis Routines software.Results585 subjects were included, the mean age was 42 (±16.7) years, 57% were women. The heritability of the severity of some GERD symptoms was h2 = 0.27, 0.27, 0.37, and 0.34 (p-value <1.0x10-5) for acidity complaints, lower abdominal complaints, sleep disturbances, and total ReQuest score, respectively. Heritability of metabolic syndrome components ranged from 0.40 for fasting plasma glucose to 0.61 for body mass index and diabetes mellitus. The heritability for fibrinogen and C-reactive protein was 0.64 and 0.38, respectively. Statistically significant genetic correlations were found between acidity complaints and fasting plasma glucose (ρG = 0.40); sleep disturbances and fasting plasma glucose (ρG = 0.36); acidity complaints and diabetes mellitus (ρG = 0.49) and between total ReQuest score and fasting plasma glucose (ρG = 0.43). The rest of metabolic syndrome components did not correlate with GERD symptoms.ConclusionGenetic factors substantially explain the phenotypic variance of the severity of some GERD symptoms, metabolic syndrome components and inflammation markers. Observed genetic correlations suggest that these phenotypes share common genes. These findings suggest conducting further investigation, as the determination of a linkage analysis in order to identify regions of susceptibility for developing of GERD and metabolic syndrome.

show abstract

“…Pantoparazole magnesium has lower maximum plasma concentration than the conventional pantoprazole sodium and thus a longer half-life. Pantoprazole-Mg 40 mg once daily for 4 weeks improved a broad range of GERD-associated symptoms from baseline, including both day- and night-time GERD symptoms [ 37 ].…”

Section: Treatment Of Refractory Gastroesophageal Reflux Diseasementioning

confidence: 99%

Refractory gastroesophageal reflux disease

Subramanian

Triadafilopoulos

2014

Gastroenterology Report

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of stomach contents into the esophagus causes troublesome symptoms, esophageal injury, and/or complications. Use of proton pump inhibitors (PPI) remains the standard therapy for GERD and is effective in most patients. Those whose symptoms are refractory to PPIs should be evaluated further and other treatment options should be considered, according to individual patient characteristics. Response to PPIs could be total (no symptoms), partial (residual breakthrough symptoms), or absent (no change in symptoms). Patients experiencing complete response do not usually need further management. Patients with partial response can be treated surgically or by using emerging endoscopic therapies. Patients who exhibit no response to PPI need further evaluation to rule out other causes.

show abstract

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

Cited by 9 publications

References 24 publications

Validation and Diagnostic Usefulness of Gastroesophageal Reflux Disease Questionnaire in a Primary Care Level in Mexico

Validation and Diagnostic Usefulness of Gastroesophageal Reflux Disease Questionnaire in a Primary Care Level in Mexico

Heritability and genetic correlation between GERD symptoms severity, metabolic syndrome, and inflammation markers in families living in Mexico City

Refractory gastroesophageal reflux disease

Contact Info

Product

Resources

About